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Reducing Agents Structurally Related to Catechols 
as Inhibitors of DNA Synthesis in Mammalian Cells 
S incc thc initi al rcports showin g that catecho lam.ines rc-lated to levodopa and do pamin e have antitumo r activity aga inst hum an and experimcntal melano m a [1 -3], a numbcr of in vestigators have con fi rm ed and extended these observat io ns [4-9]. The notion has developed that 
the ca techols represent a previously unidentified class of m o lecules 
that are ca pable of inhibiting DNA sy nthesis in a variety of eu-
karyotic and proka ryotic cells as diverse as m elanotic and am el-
ano tic m elanoma, leukemia, norm al Iymphocytcs, norm al and 
m ali gnant epiderm al cells, and even in cell s derived fro m fun gi 
and bacteria . Ea rl y in th e study of these mo lecul es it was apparent 
that, in additi on to the clini ca l potential of these agents, an un-
de rstandin g o f th e rem arkable selectivity that they ex hibited to-
ward m ali gnant cell s mig ht provide impo rtant biochemi ca l in-
for m ati on concernin g metabo li c differences between no rmal and 
m ali gnant cells. Interes tin g ly, a review of the derma tologic lit-
era ture revea led that spo radi c accounts of the bio logic activity of 
simi lar co mpo unds had appea red. Po lyhydroxy lated co mpound s, 
like py roga llo l, had been used ex tensivel y prio r to the ava ilability 
of ste ro ids as anti-inAamm ato ry agents, w hil e levodopa had been 
cva lu ated in the treatment o f proliferativc sk in disorders Iikc pso-
riasis with in consistent resul ts. SimiiJ rly, many crude pl ant prep-
arations had bccn used topica ll y w ith signi fiC:1I1t anti-inAamma-
tory activity that might now be attributed to the high concentrations 
of plant catecho ls p resent. We shall rev iew recent developments 
that appear to suggest that th e inhibitory effe cts upon ON A syn-
thesis arc attrib utable to previously un suspected , intracellul ar 
m etaboli c properties of ca techols, and mi ght be a fundamental 
and impo rtant property of biolog ic redu cin g agents that arc ca-
pable of undergo in g redox reacti o ns w ithin specifi c electroni c 
potentia l ranges. 
M ECHANISM OF AC TION 
The first obse rvations concernin g the uniqu e properti es of these 
compo unds were es tablished usin g naturall y occur ri ng ca techo ls 
related to levodo pa and do pamine. Throug h chemi ca l m anipu-
lat io n it was possible to prepa re ana logs of the naturally occurrin g 
catecho lamin es that retained the ca techo l moi ety but were com-
pletely devo id o f ca techo lamin e agonist act ivity . T hese synth eti c 
ana logs se rved to cla rify the point that the antipro liferative activity 
o bservcd was not a consequence o f th eir ad renerg ic properties 
but resided in the catecho l moiety itse lf. The prototype compound 
prepared was 3,4-dih ydro xy benzy lamine (N SC 263475), w hi ch 
had m uch g rea ter antitum or and antipro liferati ve activity , espe-
ciall y in vivo, since the toxicity observed was due to unwanted 
adrenerg ic effects, which were tota ll y lack in g in this derivative 
110] . We now had a tool w ith w hi ch we could stud y the m etabo li c 
intrace llubr effects of ca techo ls in the absence of interferin g ad-
renergic effects. T hese rel ationships mi g ht also ex plain the pre-
vio us lack o f observat ions reported with catechola min es, since 
ca rdi o vascul ar effects occurred at co ncentratio ns that were fn:-
quently 10 times less than the concentratio ns necessa ry for the 
antipro liferative effect. 
With the advent of the modified catecho lamines, we w ere ab le 
to in vest igate the biochemical bas is of th e anti proliferative effect 
as well as the rem arka ble selecti vity that the substan ces appeared 
to exert upon replicatin g cells. Initial ex perim ents reveal ed a char-
acteristic patte rn of responses caused by the dihydroxybenzcne 
derivatives. First, there was an ca rl y (5 min) total inhibitio n of 
thymidine in co rpo rat io n with co rrcsponding 'li ttle effect upon 
leucine and uridine incorporation . Second, structure-activity studies 
w ith over 30 ana logs showed tha t bio logic act ivity resided entirely 
in the 1,2-d ih ydroxy benzene portion o f the m o lecu le. Third , the 
inhibiti on was very selective. Using an ex perimenta l technique 
develo ped fo r th e study of the relative effects of dru gs upon tumor 
cells and other rep lica tin g cells, essentia ll y co mplete suppression 
o f the L 1210 leukemia o r B-16 melano m a tumor cell replication 
could be achieved with littl e or no effect upon the other primary 
repli catin g tissues, bone m arrow and gastrointestinal mucosa. 
Thi s se lectivity was much g rea ter than that observed with other 
inhibi to rs such as methotrexate and 5-Auorouracil. 
At this point, we were m ade awa re of an interes tin g parallel 
series of in vestigatio ns w hereby the mechanism of sporul ation of 
the common mushroom, Agariws bisporlls, was elu cidated [11 ]. 
T his mushroom contains very high tyrosinase activity and is able 
to tota ll y cease g rowth , in vo luting to fo rm spores, in the presence 
of un favorab le g rowing condit io ns. T his phenomenon is m e-
diated by generat in g natural catecho l-like substan ces stru cturally 
related to levodopa throu g h the act io n of tyrosinase upon inactive 
phenolic substrates. The similari ty in both structure and function 
of these co mpound s to o-dihyd rox y catechols suggested that an 
impo rtant general property la y in the dihydroxy ben zene m oiety 
that has been utili zed in natural syste ms to inhibit replicative 
enzy m es . T his observatio n ha s given add itional impetu s to th e 
understand in g of the bio logic basi s o f this act ivity, since the idea 
was novel that there mi g ht be bio logic act ivities m ed iated by 
ca techo ls thro ugh intracellular mechan isms other than those that 
medi ate the ad renergic act ivities, and mig ht be u tilized by a w ide 
va ri ety of natural sys tem s. 
In orde r to define the m o lecular basis o f th ese o bserva tio ns, we 
have attempted to determine the enzy mati c targets invo lved . As 
mentio lled ea rli er, the stru ctural elements that appear necessa ry 
for ac tivity arc the 1,2-dihydroxybenzene mo iety; add iti onal h y-
dro xy l groups can be present but the para iso m ers that have been 
studied m ost often in th e past arc totally inactive. It appears that 
the inhibito ry pheno m enon depcnds upo n a very specific redox 
potenti al of th e ca techo ls, indi ca tin g the red uced form of the 
quin ol is the ac tive form, although much o f the emph asis on the 
study of these compo unds, especiall y in melanoma , has previ-
ously focused upon the quinone or oxidized forms. 
We have identifi ed signifi ca nt inhibitory activity against severa l 
important O N A repli ca tive enzy mes including ribonucleotide re-
ductase, thymidylate synthetase, and DNA polymerase [12] . There 
is a co mm on linkage in the fun cti o n of these enzy mes which, in 
add iti on to showin g sensitivity to rcdo x reagents, arc all appar-
ently physica lly linked together in a co mpl ex ca ll ed the replitase 
w here D NA synthetic activity occurs. 
Detail ed studies have shown that the ca techo ls inhibit ribo-
nucleotide reductase differently th an hydroxyurea, the onl y other 
known inhibi tor of this impo rtant enzym e. T hi s mig ht have sig-
0022-202X/1l7 1$03.50 opyright © 1987 by The Society fo r In vestiga ti ve Dermatology, Inc. 
532 
VOL. 88, NO.5 MAY 1987 
nifica nce sin ce the contro l of DN A synthesis in m ammalian cell s 
is primaril y regulated by the suppl y of deoxynucleotides, w hich 
in turn is reg ul ated by the activity of ribonucleotide red uctase. 
Importantly, other than hydroxyurea no clinica ll y effecti ve in-
hibi to rs of this important enzym e have been identified, even though 
th is enzy me is a m ajo r co ntro l point of the rate of DN A sy nth esis 
in mammalian cells. 
M ost recentl y our work has focused o n the concept that it is 
not a specific enzy m e that mi ght be the target of the catechols, 
but rather the introducti on of a powerful red ucin g agent of the 
appropriate redox potential as represented by the o- catechols can 
genera ll y alter the redox confi g uration of the cell and mimi c an 
electro ni c state of depleted reduced precurso rs . It mi ght be of 
signifi ca nce that m any of the enzy mes that appear crucial to the 
synthesis of DNA arc also particularly sensiti ve to redox con-
diti o ns. 
T h ese phenomena mig ht also contribu te to the select ivity o b-
served between normal and mali gnant cells sin ce there is a sub-
stantial difference in the way in which the two can m anipul ate 
free rad ica ls and respond to redox perturbations thro ugh differ-
ences in g lu tathione metabolism. 
An additiona l interestin g aspect of the mechanism of actio n of 
a quino l-Iike substa nce is that the quino l itself is con verted to the 
quinone o nce the reduction has taken place and the hig hl y elec-
trop hili c quinone is itself ca pable of inhibi tin g a va riety of en-
zymes, especiall y those that arc dependent upon NH2 or SH groups. 
T hi s biva lency mig ht have impo rtant practica l significa nce. For 
exa mple, we have attempted to g row cel l lines that arc resista nt 
to the inhibito ry effects of the ca techo ls in an attempt to develop 
mutants to assist in the elu cidation of the m echani sm . H owever, 
after g rowin g cell s continuo usly fo r three yea rs we have been 
unab le to develop mutants , whereas res ista nt Illutants are easil y 
ob ta inable with other agents such as hydroxyurea. Although no t 
es tablished, this might be the direct res ult of the fact that the 
quinol mig ht affect one target, and in so do ing is converted to 
the quinone that is capa ble of inhibiting other targets, thereby 
req uiring multiple co ncurrent mutations to achieve sign ifi cant 
res ista nce. 
1n summ ary, it is clear that there is a genera l phenomenon of 
inhibitio n that is observed bo th in mel ano ma and no n mel ano ma 
cell s that is related to the red uced form of the ca techol. The 
in hibitory phenomenon is aug mented in tyrosinase-containin g 
cell s, e.g . mel anotic melan o ma , beca use these cells ca n convert 
th e reduced ca techo l to the highl y reactive electrophilic quinone 
that contributes to the bas ic cyto tox icity . This aspect might also 
be r e levant to a lesser ex tent in nonm elanom3 cells, sin ce man y 
cell s arc known to contain other ox idases and furth erm o re the 
inhibition of th e red uctase itself mi g ht yield ox idized quinone as 
a s ide product. 
M ost recently we Inve shown that, in ad dition to the action 
of the agents upo n both human and m o use mali gnant melanoma 
and experimental leukemia, several other intri guin g applica tions 
have been identified. For exa mple, in this journal we In ve shown 
that the agents arc quite effective in the inhibitio n of replication 
of epider m al- derived cells and that epiderm al cells alT quite sen-
sitive [1 3]. We are currentl y in vestigatin g the effects of these 
red u cing agents upo n nonmali gnant repli catin g epiderm al cells. 
HUMAN TUDI ES 
Because of the uniqu e pro perties of the ca techo ls and the fac t that 
they were ava ilable for use in hum ans, pendin g the availability 
of d erivatives of decreased toxicity, we were in a unique position 
to evaluate the potcntial clinica l re leva nce of these observa tions 
to humans. We initia ll y studied the effects of dopamine and werc 
able to dem o nstrate inhibition of DN A synthcsis in 4 patients 
w ith advanccd disease. Im portantly, we were also able to confirm 
in these patients the inhibito ry effect upo n bone marrow and 
dem o nstrate the hithcrto unsuspected ability of the ca tccho l-
amine, dopamine, to inhibit replication of bone m arrow [14]. 
Dopamine, expectedly, proved too toxic to provide a practical 
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treatment for m elano ma; additiona l studies with the less toxic 
combin ation of Icvodopa-carbidopa were underta ken in selected 
paticnts and confirm ed antitumor responses werc observed. We 
have continued to treat selective patients pcnding the preclinica l 
approva l of the improved nonadrcnergic analogs, but the avai l-
ability of the former agents has provided unique and important 
data 11 51· 
These studics also provided an opportunity to evaluate the 
effects of catechols upon lymphocytes dcrived from patients w ith 
m clano m a and confirmed that the catechols were indeed able to 
inhibit the blastogenic res po nse of the lymphocytes. In view of 
the variety of immuno logic hypotheses concerning melanoma, it 
is intcresting to specul ate as to the extent to w hich immuno-
m odul ation contributed to the observed clinical responses. T hese 
results also provided a po tential ex planation of the previously 
observed pheno m enon that quinols related to a-methyldopa were 
capa ble of inhibiting T - cell derived lymphocy tes [16]. 
CO N CLU SIO N 
As new data co ntinue to be available, they arc leading to a de-
scripti on of som e of the m ost complex aspects of cellular metab-
o lism th at invo lve redox potentia ls . In addition to the potential 
clinica l acti vity of the agents in thc tre:ltment of melanoma and 
rclated diseases, a number of other important questions remain. 
Amon g these arc: What arc the implica tions of this work to other 
nonneoplastic proliferative diseases in cl uding those dc rm atolog-
ica ll y and immuno logica ll y m ed iated? To what extcnt do the 
phenomena oper:ltivc here refl ect normal controlmcchanis ms that 
arc uscd to provide initial contro l over D NA repli ca tion through 
m oni torin g of the ava ilabi lity of red ucin g power? Are thesc phe-
no mena impo rtant to prokaryotic cells, sin ce catechols arc also 
ca pable of inhibiting these ce ll s? Several enzy m e targets have been 
iden tifi ed as scnsitive to thc action of reducin g agents; arc these 
all of the releva nt enzy mes, and arc they adequate to account for 
the inhibito ry activity of these agents? Finall y, ca n we now begin 
to add ress the very impo rtant question of selectivity? 
In conclu sion , the story has been interest in g but in co mplete, 
and illustrates in a sm all way the tortuous road that scicntific 
in vestigations fo llow and how unan ticipated the rcsults often arc. 
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